6 New Approved Drugs for Primary Care: Q1 2023

Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows

Slideshow

From type 2 diabetes to migraine, we have picked the top 6 FDA-approved drugs every primary care physician should know about from the first quarter.

At the close of the first quarter of a new year, Patient Care Online has compiled a list of 6 new US Food and Drug Administration (FDA)-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults; a novel fixed dose combination of albuterol and budesonide for the treatment of asthma; and 4 more.

Related Content

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.

November 19th 2025

Longitudinal Blood Biomarkers Show Promise for Monitoring Alzheimer's Disease Progression in Subjective Cognitive Decline

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Blood-based monitoring could enable earlier intervention as approximately 20% of initially negative participants transitioned to positive biomarker status.

November 13th 2025

Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

T6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial / image credit ©Designua/stock.adobe.com

Quality Improvement Program Greatly Expands Sleep Apnea Testing After Stroke in VA Hospitals

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.

Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows

The study supports the feasibility of structured operational strategies to narrow dangerous gaps in guideline-recommended inpatient OSA testing, authors wrote.

Related Content

Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights

A multinational survey of HS specialists in Europe found that 81% prescribe antibiotics despite expecting poor response and 79% favor earlier biologic initiation.

November 19th 2025

Longitudinal Blood Biomarkers Show Promise for Monitoring Alzheimer's Disease Progression in Subjective Cognitive Decline

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

Blood-based monitoring could enable earlier intervention as approximately 20% of initially negative participants transitioned to positive biomarker status.

November 13th 2025

Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

Quality Improvement Program Greatly Expands Sleep Apnea Testing After Stroke in VA Hospitals

KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.